{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:24Z","timestamp":1786982724104,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40122-015-0034-x","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T05:46:41Z","timestamp":1429508801000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability"],"prefix":"10.1007","volume":"4","author":[{"given":"Marie Louise","family":"Navez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Monella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"B\u00f6sl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1742-1241.2009.02089.x","volume":"63","author":"RW Johnson","year":"2009","unstructured":"Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract. 2009;63:1386\u201391.","journal-title":"Int J Clin Pract"},{"issue":"Suppl. 1","key":"34_CR2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jpain.2007.10.008","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Gnann JW, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(Suppl. 1):S37\u201344.","journal-title":"J Pain."},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/0002512-200825120-00002","volume":"25","author":"RW Johnson","year":"2008","unstructured":"Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia. Optimizing management in the elderly patient. Drugs Aging. 2008;25:991\u20131006.","journal-title":"Drugs Aging"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.","journal-title":"BMC Med"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10389-011-0481-8","volume":"20","author":"K Lukas","year":"2012","unstructured":"Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health. 2012;20:441\u201351.","journal-title":"J Public Health."},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40266-012-0014-3","volume":"29","author":"S Nalamachu","year":"2012","unstructured":"Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29:863\u20139.","journal-title":"Drugs Aging"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341\u20139.","journal-title":"Mayo Clin Proc"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","volume":"137","author":"A Gauthier","year":"2009","unstructured":"Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38\u201347.","journal-title":"Epidemiol Infect"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1471-2334-10-230","volume":"10","author":"LE Gialloreti","year":"2010","unstructured":"Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.","journal-title":"BMC Infect Dis"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/1471-2334-11-302","volume":"11","author":"AM Cebri\u00e1n-Cuenca","year":"2011","unstructured":"Cebri\u00e1n-Cuenca AM, D\u00edez-Domingo J, San-Mart\u00edn-Rodr\u00edguez M, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain. BMC Infect Dis. 2011;11:302.","journal-title":"BMC Infect Dis"},{"issue":"Suppl","key":"34_CR11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl):S3\u201314.","journal-title":"Mayo Clin Proc"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"1113-e88","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88.","journal-title":"Eur J Neurol"},{"key":"34_CR13","doi-asserted-by":"crossref","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015. (Epub ahead of print).","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"34_CR14","unstructured":"Boesl I, Koenig S. More than 20 million patients used 5% lidocaine medicated plaster: an update on its safety profile. PainWeek. 2014. http:\/\/conference.painweek.org\/media\/mediafile_attachments\/04\/724-painweek2014acceptedabstracts.pdf . Accessed Mar 24, 2015."},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0304-3959(95)00146-8","volume":"65","author":"MC Rowbotham","year":"1996","unstructured":"Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39\u201344.","journal-title":"Pain"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0304-3959(98)00244-9","volume":"80","author":"BS Galer","year":"1999","unstructured":"Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533\u20138.","journal-title":"Pain"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1185\/03007990903047880","volume":"25","author":"R Baron","year":"2009","unstructured":"Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25:1663\u201376.","journal-title":"Curr Med Res Opin"},{"key":"34_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200929060-00003","volume":"29","author":"A Binder","year":"2009","unstructured":"Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29:393\u2013408.","journal-title":"Clin Drug Investig"},{"key":"34_CR19","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1185\/03007995.2010.483675","volume":"26","author":"S Rehm","year":"2010","unstructured":"Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26:1607\u201319.","journal-title":"Curr Med Res Opin"},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1185\/03007990902901368","volume":"25","author":"G Hans","year":"2009","unstructured":"Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25:1295\u2013305.","journal-title":"Curr Med Res Opin"},{"key":"34_CR21","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1185\/03007995.2012.707977","volume":"28","author":"R Sabatowski","year":"2012","unstructured":"Sabatowski R, Hans G, Tacken I, et al. Safety and efficacy outcomes of long-term treatment up to 4\u00a0years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 2012;28:1337\u201346.","journal-title":"Curr Med Res Opin"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archinte.163.5.628","volume":"163","author":"BS Galer","year":"2003","unstructured":"Galer BS, Gammaitoni AR. More than 7\u00a0years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med. 2003;163:628.","journal-title":"Arch Intern Med"},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1185\/03007995.2012.690339","volume":"28","author":"G Mick","year":"2012","unstructured":"Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster\u2014a review. Curr Med Res Opin. 2012;28:937\u201351.","journal-title":"Curr Med Res Opin"},{"key":"34_CR24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1526-4637.2002.02050.x","volume":"3","author":"NP Katz","year":"2002","unstructured":"Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324\u201332.","journal-title":"Pain Med."},{"key":"34_CR25","unstructured":"Electronic Medicines Compendium. Versatis 5% medicated plaster. Summary of product characteristics. http:\/\/www.medicines.org.uk\/emc\/medicine\/19291\/SPC\/Versatis+5++Medicated+Plaster\/ . Accessed Feb 2014."},{"key":"34_CR26","first-page":"551","volume":"7","author":"S Nalamachu","year":"2013","unstructured":"Nalamachu S, Wieman M, Bednarek L, et al. Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia. Patient Prefer Adherence. 2013;7:551\u20137.","journal-title":"Patient Prefer Adherence."},{"key":"34_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.pain.2011.08.020","volume":"153","author":"EK Krumova","year":"2012","unstructured":"Krumova EK, Zeller M, Westermann A, et al. Lidocaine patch (5%) produces a selective, but incomplete block of A\u03b4 and C fibers. Pain. 2012;153:273\u201380.","journal-title":"Pain"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/ajhp\/59.22.2215","volume":"59","author":"AR Gammaitoni","year":"2002","unstructured":"Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm. 2002;59:2215\u201320.","journal-title":"Am J Health Syst Pharm."},{"key":"34_CR29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1744-8069-4-47","volume":"4","author":"MN Baliki","year":"2008","unstructured":"Baliki MN, Geha PY, Jabakhanji R, et al. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain. 2008;4:47.","journal-title":"Mol Pain."},{"key":"34_CR30","first-page":"77","volume":"3","author":"G Correa-Illanes","year":"2010","unstructured":"Correa-Illanes G, Calder\u00f3n W, Roa R, et al. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local Reg Anesth. 2010;3:77\u201383.","journal-title":"Local Reg Anesth."},{"key":"34_CR31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00415-005-0717-z","volume":"252","author":"G Wasner","year":"2005","unstructured":"Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005;252:677\u201386.","journal-title":"J Neurol"},{"key":"34_CR32","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1517\/14656566.2011.601868","volume":"12","author":"B Gustorff","year":"2011","unstructured":"Gustorff B, Hauer D, Thaler J, et al. Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models\u2014two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers. Expert Opin Pharmacother. 2011;12:2781\u201390.","journal-title":"Expert Opin Pharmacother"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10133","volume":"91","author":"BJ Campbell","year":"2002","unstructured":"Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91:1343\u201350.","journal-title":"J Pharm Sci"},{"key":"34_CR34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1345\/aph.1A185","volume":"36","author":"AR Gammaitoni","year":"2002","unstructured":"Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36:236\u201340.","journal-title":"Ann Pharmacother"},{"key":"34_CR35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-197803030-00001","volume":"3","author":"NL Benowitz","year":"1978","unstructured":"Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978;3:177\u2013201.","journal-title":"Clin Pharmacokinet"},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003088-200342070-00004","volume":"42","author":"G J\u00fcrgens","year":"2003","unstructured":"J\u00fcrgens G, Graudal NA, Kampmann JP. Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet. 2003;42:647\u201363.","journal-title":"Clin Pharmacokinet"},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpainsymman.2005.06.001","volume":"30","author":"IR Wilhelm","year":"2005","unstructured":"Wilhelm IR, Griessinger N, Koppert W, et al. High doses of topically applied lidocaine in a cancer patient. J Pain Symptom Manag. 2005;30:203\u20134.","journal-title":"J Pain Symptom Manag"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255\u20139.","journal-title":"Lancet"},{"key":"34_CR39","unstructured":"Rowbotham MC, Davies PS, Galer BS. Multicenter, double-blind, vehicle-controlled trial of long-term use of lidocaine patches for postherpetic neuralgia. In: Abstracts of the 8th World congress of the International Association for the Study of Pain (Vancouver BC, Canada, August 17\u201322). 1996; 274, abstract 184."},{"key":"34_CR40","first-page":"1","volume":"18","author":"BS Galer","year":"2000","unstructured":"Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today\u2019s Ther Trends. 2000;18:1\u201320.","journal-title":"Today\u2019s Ther Trends."},{"key":"34_CR41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/EJA.0b013e328330e989","volume":"27","author":"IR Wilhelm","year":"2010","unstructured":"Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. Eur J Anaesthesiol. 2010;27:169\u201373.","journal-title":"Eur J Anaesthesiol"},{"key":"34_CR42","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/papr.12079","volume":"14","author":"G Pickering","year":"2014","unstructured":"Pickering G, Pereira B, Cl\u00e8re F, et al. Cognitive function in older patients with postherpetic neuralgia. Pain Pract. 2014;14:E1\u20137.","journal-title":"Pain Pract."},{"key":"34_CR43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/TCRM.S47138","volume":"9","author":"P Bruckenthal","year":"2013","unstructured":"Bruckenthal P, Barkin RL. Options for treating postherpetic neuralgia in the medically complicated patient. Ther Clin Risk Manag. 2013;9:329\u201340.","journal-title":"Ther Clin Risk Manag"},{"key":"34_CR44","unstructured":"O\u2019Hara J, Obradovic M, Liedgens H, et al. Relationship between compliance and patient reported outcomes (PROS) in post herpetic neuralgia with insight into lidocaine medicated plaster (LMP) use. In: Abstract 170 of the 8th Congress of the European Federation of IASP Chapters (EFIC), 9\u201312 October 2013, Florence. European Pain Federation EFIC; 2013."},{"key":"34_CR45","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1213\/01.ANE.0000186348.86792.38","volume":"101","author":"IW Tremont-Lukats","year":"2005","unstructured":"Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101:1738\u201349.","journal-title":"Anesth Analg"},{"key":"34_CR46","first-page":"125","volume":"6","author":"JL Anderson","year":"1984","unstructured":"Anderson JL. Current understanding of lidocaine as an antiarrhythmic agent: a review. Clin Ther. 1984;6:125\u201341.","journal-title":"Clin Ther"},{"key":"34_CR47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0091270002239817","volume":"43","author":"AR Gammaitoni","year":"2003","unstructured":"Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43:111\u20137.","journal-title":"J Clin Pharmacol"},{"key":"34_CR48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","volume":"6","author":"G Oster","year":"2005","unstructured":"Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356\u201363.","journal-title":"J Pain."},{"key":"34_CR49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3959(97)00030-4","volume":"72","author":"C Eccleston","year":"1997","unstructured":"Eccleston C, Crombez G, Aldrich S, et al. Attention and somatic awareness in chronic pain. Pain. 1997;72:209\u201315.","journal-title":"Pain"},{"key":"34_CR50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pain.2007.03.036","volume":"130","author":"DA Seminowicz","year":"2007","unstructured":"Seminowicz DA, Davis KD. A re-examination of pain-cognition interactions: implications for neuroimaging. Pain. 2007;130:8\u201313.","journal-title":"Pain"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-015-0034-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T16:15:30Z","timestamp":1566576930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40122-015-0034-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s40122-015-0034-x","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,21]]}}}